Market Price

268.78 

4.99 1.9%

as of Oct 29 '20

52 Week Range:

55.42 306.72


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 4.36
3.95
5.48
5.97
6.39
6.31
6.58
5.98
6.34
9.86
12.76
growth rate -9.4% 38.7% 8.9% 7.0% -1.3% 4.3% -9.1% 6.0% 55.5% 29.4%
Earnings BIT 52.15
-17.42
11.48
7.61
3.43
-6.56
5.04
-4.21
36.93
114.89
105.85
growth rate -100.0% 100.0% -33.7% -54.9% -100.0% 100.0% -100.0% 100.0% 211.1% -7.9%
Avg.PE 12.76
-32.60
66.23
126.58
147.06
-30.73
416.39
416.39
-21,305.00
35.18
34.40
growth rate -100.0% 100.0% 91.1% 16.2% -100.0% 100.0% 0.0% -100.0% 100.0% -2.2%
ROA 21.27
-5.92
3.09
1.92
2.88
-1.96
-1.42
-3.47
-1.23
8.52
8.49
growth rate -100.0% 100.0% -37.9% 50.0% -100.0% 0.0% 0.0% 0.0% 100.0% -0.4%
ROE 26.77
-9.43
5.12
2.59
3.49
-3.02
-2.62
-6.59
-3.82
22.73
14.80
growth rate -100.0% 100.0% -49.4% 34.8% -100.0% 0.0% 0.0% 0.0% 100.0% -34.9%
ROIC 25.54
-6.07
4.17
2.60
3.58
-1.91
0.47
-1.06
0.49
15.88
14.42
growth rate -100.0% 100.0% -37.7% 37.7% -100.0% 100.0% -100.0% 100.0% 3,140.8% -9.2%
Cur. Ratio 4.28
3.55
3.18
3.23
3.27
7.56
7.81
6.71
2.58
1.21
1.77
growth rate -17.1% -10.4% 1.6% 1.2% 131.2% 3.3% -14.1% -61.6% -53.1% 46.3%
Quick Ratio 3.48
1.81
2.31
2.05
1.60
6.47
6.81
5.79
0.80
0.75
1.25
growth rate -48.0% 27.6% -11.3% -22.0% 304.4% 5.3% -15.0% -86.2% -6.3% 66.7%
Leverage 1.32
1.91
1.50
1.21
1.21
1.84
1.86
1.94
4.12
1.89
1.63
growth rate 44.7% -21.5% -19.3% 0.0% 52.1% 1.1% 4.3% 112.4% -54.1% -13.8%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 9.70
13.50
25.33
39.19
38.29
34.47
18.40
24.99
78.36
76.89
104.91
growth rate 39.2% 87.6% 54.7% -2.3% -10.0% -46.6% 35.8% 213.6% -1.9% 36.5%
Acct.Payable 25.47
13.88
14.44
12.42
8.68
16.05
27.28
25.17
26.70
growth rate -45.5% 4.0% -14.0% -30.2% 85.0% 70.0% -7.7% 6.1%
Cur.Assets 126.20
56.00
104.38
74.77
78.62
274.48
240.66
225.39
331.23
193.40
222.23
growth rate -55.6% 86.4% -28.4% 5.1% 249.1% -12.3% -6.3% 47.0% -41.6% 14.9%
Total Assets 166.30
214.60
278.89
242.10
271.49
447.41
406.51
388.25
935.25
806.37
910.87
growth rate 29.0% 30.0% -13.2% 12.1% 64.8% -9.1% -4.5% 140.9% -13.8% 13.0%
Cash 89.00
6.80
61.33
14.86
9.36
200.90
191.47
169.51
36.09
43.70
52.78
growth rate -92.4% 801.9% -75.8% -37.0% 2,047.0% -4.7% -11.5% -78.7% 21.1% 20.8%
Inventory 15.00
17.70
14.31
15.50
27.64
24.76
26.39
26.05
67.08
67.38
58.09
growth rate 18.0% -19.2% 8.3% 78.4% -10.4% 6.6% -1.3% 157.6% 0.5% -13.8%
Cur.Liabilities 29.50
15.80
32.93
22.50
24.01
36.39
30.83
33.61
128.35
159.74
125.89
growth rate -46.4% 108.4% -31.7% 6.7% 51.6% -15.3% 9.0% 281.9% 24.5% -21.2%
Liabilities 39.90
102.10
93.51
42.32
47.71
202.40
187.83
187.62
708.15
380.79
351.05
growth rate 155.9% -8.4% -54.7% 12.7% 324.3% -7.2% -0.1% 277.4% -46.2% -7.8%
LT Debt 6.50
79.80
47.95
10.57
5.13
137.96
143.30
144.34
377.26
53.19
0.00
growth rate 1,127.7% -39.9% -78.0% -51.5% 2,591.3% 3.9% 0.7% 161.4% -85.9% -100.0%
Equity 126.50
112.50
185.39
199.78
223.78
245.01
218.68
200.63
227.10
425.58
559.82
growth rate -11.1% 64.8% 7.8% 12.0% 9.5% -10.8% -8.3% 13.2% 87.4% 31.5%
Common Shares 30.00
29.00
33.00
34.00
35.00
34.00
34.00
33.00
34.00
43.00
43.00
growth rate -3.3% 13.8% 3.0% 2.9% -2.9% 0.0% -2.9% 3.0% 26.5% 0.0%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 6.90
6.50
4.85
12.22
20.82
11.24
17.03
11.91
17.51
31.69
27.23
growth rate -5.8% -25.3% 151.8% 70.4% -46.0% 51.5% -30.1% 47.0% 81.0% -14.1%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 72.80
-10.21
47.54
19.63
25.68
35.69
36.88
11.82
27.71
136.35
134.49
growth rate -100.0% 100.0% -58.7% 30.8% 39.0% 3.4% -68.0% 134.5% 392.1% -1.4%
FCF per Share 2.16
-0.73
0.85
-0.24
0.41
0.18
0.69
-0.05
0.48
1.90
2.38
growth rate -100.0% 100.0% -100.0% 100.0% -56.1% 283.3% -100.0% 100.0% 295.8% 25.3%
Sale Purchase of Stock 58.62
1.26
5.77
4.78
2.91
8.58
24.89
growth rate -97.9% 359.1% -17.2% -39.1% 194.6% 190.2%
FCF 66.00
-21.00
26.00
-8.00
3.00
24.00
19.00
-0.09
10.00
105.00
107.00
growth rate -100.0% 100.0% -100.0% 100.0% 700.0% -20.8% -100.0% 100.0% 950.0% 1.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 164.30
113.30
158.60
155.74
177.33
184.16
194.03
191.60
277.74
522.29
534.89
growth rate -31.0% 40.0% -1.8% 13.9% 3.9% 5.4% -1.3% 45.0% 88.1% 2.4%
Op.Income 52.50
-15.30
7.63
4.99
7.39
-6.56
5.04
-4.21
36.93
114.89
105.85
growth rate -100.0% 100.0% -34.6% 48.0% -100.0% 100.0% -100.0% 100.0% 211.1% -7.9%
IBT 52.10
-17.40
11.48
7.61
3.43
-10.98
-9.30
-16.20
-8.04
63.38
77.18
growth rate -100.0% 100.0% -33.7% -54.9% -100.0% 0.0% 0.0% 0.0% 100.0% 21.8%
Net Income 32.90
-11.30
7.63
4.99
7.39
-7.07
-6.08
-13.81
-8.17
74.18
72.92
growth rate -100.0% 100.0% -34.6% 48.0% -100.0% 0.0% 0.0% 0.0% 100.0% -1.7%
EPS 1.08
-0.39
0.23
0.15
0.21
-0.21
-0.18
-0.42
-0.24
1.86
1.73
growth rate -100.0% 100.0% -34.8% 40.0% -100.0% 0.0% 0.0% 0.0% 100.0% -7.0%
Gross Profit 109.10
60.70
95.74
94.46
110.35
109.07
118.01
111.25
167.01
319.36
320.81
growth rate -44.4% 57.7% -1.3% 16.8% -1.2% 8.2% -5.7% 50.1% 91.2% 0.5%
R&D 12.50
23.70
26.33
27.72
34.19
37.91
35.51
38.67
33.64
51.65
52.55
growth rate 89.6% 11.1% 5.3% 23.3% 10.9% -6.3% 8.9% -13.0% 53.5% 1.8%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 7.65
25.14
38.46
53.54
84.54
growth rate 228.4% 53.0% 39.2% 57.9%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 57.08
86.75
104.91
110.79
120.42
growth rate 52.0% 20.9% 5.6% 8.7%
Acct.Payable 24.84
30.40
26.70
33.15
37.47
growth rate 22.4% -12.2% 24.2% 13.0%
Cur.Assets 157.51
185.41
222.23
286.48
296.94
growth rate 17.7% 19.9% 28.9% 3.7%
Total Assets 846.18
867.52
910.87
966.77
972.93
growth rate 2.5% 5.0% 6.1% 0.6%
Cash 28.55
28.91
52.78
108.77
72.59
growth rate 1.3% 82.5% 106.1% -33.3%
Inventory 64.62
61.74
58.09
58.71
92.62
growth rate -4.5% -5.9% 1.1% 57.8%
Cur.Liabilities 112.11
127.17
125.89
136.20
182.98
growth rate 13.4% -1.0% 8.2% 34.4%
Liabilities 336.22
333.35
351.05
361.57
361.22
growth rate -0.9% 5.3% 3.0% -0.1%
LT Debt 18.19
growth rate
Equity 509.96
534.16
559.82
605.20
611.71
growth rate 4.8% 4.8% 8.1% 1.1%
Common Shares 0.04
0.04
0.04
0.04
0.04
growth rate 2.4% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 6.79
6.93
8.51
5.88
7.50
growth rate 2.1% 22.8% -30.9% 27.5%
Cash Dividends
growth rate
Cash From OA 40.53
13.33
47.72
61.18
59.00
growth rate -67.1% 258.0% 28.2% -3.6%
Sale Purchase of Stock
growth rate
FCF 33.74
6.40
39.21
55.30
51.49
growth rate -81.0% 512.9% 41.0% -6.9%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 108.25
126.49
152.18
174.65
201.75
growth rate 16.9% 20.3% 14.8% 15.5%
Op.Income 7.65
25.14
38.46
53.54
84.54
growth rate 228.4% 53.0% 39.2% 57.9%
IBT 0.57
17.53
32.51
48.82
80.20
growth rate 3,002.7% 85.5% 50.2% 64.3%
Net Income 1.27
16.18
30.63
40.24
67.65
growth rate 1,174.1% 89.3% 31.4% 68.1%
EPS
growth rate
Gross Profit 59.18
75.86
94.84
114.99
148.75
growth rate 28.2% 25.0% 21.3% 29.4%
R&D 11.72
11.98
14.92
16.38
20.97
growth rate 2.2% 24.6% 9.8% 28.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (77.70)

YOY Growth Grade:

E (29.16)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 43.46 75.65 9.89
EPS / Growth 39.6% 3.55 7.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 25.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 7.2% 24.2% 24.2%
Future PE 9.89 33.88 33.88
Future EPS 7.12 30.91 30.91
Value Price
MOS %
17.40
-93.5%
258.85
-3.7%
258.85
-3.7%
MOS Price 8.70 129.43 129.43
IRT 25.96 12.71 12.71

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.